Stiff Person Syndrome

What is stiff person syndrome?

Stiff person syndrome is a rare autoimmune neurologic disorder characterized by fluctuating muscle rigidity and painful, debilitating spasms. This condition primarily affects adults between the ages of 40 and 60, with a notable female predominance. Early recognition is important because the condition is frequently misdiagnosed as generalized anxiety disorder, functional neurologic disorder, or parkinsonism, which delays targeted treatment and increases the risk of falls and skeletal injuries. Recognition of the disorder in its early stages is essential to help preserve mobility and manage progressive disability.

What causes stiff person syndrome?

The underlying driver of the condition is impaired GABAergic inhibitory neurotransmission in the central nervous system. This loss of inhibition leads to unchecked motor neuron activity and sustained muscle contraction. In most classic cases, the immune system produces anti-glutamic acid decarboxylase antibodies (anti-GAD antibodies) that target GAD65, the rate-limiting enzyme for gamma-aminobutyric acid (GABA) synthesis. A lack of GABA causes an imbalance between excitatory and inhibitory signals in the central nervous system.

Autoimmune susceptibility may play a role, as the syndrome is frequently associated with other autoimmune diseases, including type 1 diabetes, thyroiditis, and vitiligo. A paraneoplastic variant also exists, most classically associated with breast cancer and anti-amphiphysin antibodies. In these cases, the immune response is triggered by an underlying malignancy.

What are the signs and symptoms of stiff person syndrome?

Progressive axial rigidity is the hallmark symptom, typically starting in the lumbar and thoracic paraspinal muscles and creating a characteristic “board-like” posture. This stiffness often results in exaggerated lumbar lordosis (an inward curvature of the lower spine) that restricts bending and turning. Patients experience episodic, agonizing spasms that can be triggered by sudden noises, light touch, sudden movement, or emotional stress. These spasms may be intense enough to cause bone fractures or joint dislocations in some individuals.

As the disease advances, rigidity can spread to the proximal limbs, severely impairing walking and leading to frequent, uncontrolled falls. In severe SPS-spectrum disorders, respiratory muscles, brainstem function, or autonomic function may become involved, and severe uncontrolled episodes can become life-threatening. Chronic disability also contributes to significant psychiatric symptoms, including task-specific phobias and severe anticipatory anxiety related to the fear of falling in open spaces.

How is stiff person syndrome diagnosed?

Clinicians diagnose the disorder through a combination of history, physical examination, and specialized testing. The diagnostic process focuses on classic features such as progressive axial stiffness, stimulus-triggered spasms, hyperlordosis, paravertebral stiffness, and gait dysfunction. An EMG (electromyography) is a critical diagnostic tool, as it typically reveals continuous motor unit activity in agonist and antagonist muscles even when the patient is at rest. This finding supports the diagnosis and helps distinguish the disorder from other causes of stiffness or spasticity.

Laboratory evaluation primarily targets high-titer anti-GAD antibodies in the serum and, in some cases, cerebrospinal fluid. While low titers may be seen in type 1 diabetes, titers in this syndrome are typically much higher. Magnetic resonance imaging (MRI) of the brain and spine is generally unremarkable but is often used to rule out structural causes of rigidity, such as myelopathy or spinal cord tumors. Screening for malignancy is also recommended when a paraneoplastic form is suspected, especially in patients with atypical features or antibodies such as anti-amphiphysin.

How is stiff person syndrome treated?

The main goals of stiff person syndrome treatment are to reduce spasms and control the autoimmune process. Symptomatic relief is usually achieved with high-dose benzodiazepines, such as diazepam, or baclofen, which help reduce muscle tone and the frequency of spasms. Other medications, such as tizanidine or gabapentin, may be added when needed. For patients with disabling symptoms that do not respond sufficiently to these agents, IVIG (intravenous immunoglobulin) is considered the first-line immunotherapy.

Refractory cases may require specialist-directed immunotherapies such as plasma exchange, rituximab, corticosteroids, or other immunosuppressive medications. Comprehensive stiff person syndrome therapy also includes physical and occupational therapy to maintain mobility, reduce fall risk, and adapt to functional changes. Addressing comorbid autoimmune conditions and managing psychiatric symptoms such as depression and anxiety are essential components of a multidisciplinary care plan.

What are the most important facts to know about stiff person syndrome?

• Stiff person syndrome involves impaired GABAergic inhibition, leading to progressive muscle stiffness and sensory-triggered spasms.
• High-titer anti-GAD antibodies are present in most people with classic SPS and are an important diagnostic marker.
• The condition often leads to a stiff, statue-like gait and “board-like” rigidity, significantly increasing the risk of serious injury from falls.
• While a cure is not currently available, stiff person syndrome treatment with IVIG and GABA-enhancing drugs can significantly improve symptoms and quality of life.
• The long-term outlook varies. Many people improve with treatment, but severe or poorly controlled disease can lead to serious injuries, respiratory complications, or autonomic complications.